COSETTE PHARMS NC
GenericsCOSETTE PHARMS NC is a generic drug manufacturer focused on Dermatology, Infectious Disease, Cardiovascular.
COSETTE PHARMS NC's Key Drugs
COSETTE PHARMS NC's core commercial portfolio centers on PROMETHAZINE HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE, CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE, CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, spanning Dermatology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
COSETTE PHARMS NC's Recent FDA Approvals
New NDA/BLA approvals for COSETTE PHARMS NC over the last two years — novel drugs only, excluding generics and label supplements.
COSETTE PHARMS NC's Therapeutic Areas
COSETTE PHARMS NC's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
COSETTE PHARMS NC's Top Competitors
COSETTE PHARMS NC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
COSETTE PHARMS NC Pipeline Snapshot
Active clinical trials for COSETTE PHARMS NC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PROMETHAZINE HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 1973-10-10
- Latest
- 2025-12-29
- Applications
- 109